Trial Profile
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 05 Sep 2017
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Diagnostic-imaging-abnormalities
- Focus Diagnostic use
- 30 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 02 May 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.